Bio-Techne Introduces Ultra-Sensitive Simple Plex Assays on ELLA Platform

New Assays Deliver Femtogram-Level Detection for Neurological Biomarkers

Bio-Techne has launched a new suite of ultra-sensitive Simple Plex™ assays on its ELLA™ automated immunoassay platform, enabling researchers to detect extremely low concentrations of protein biomarkers relevant to neurological disease research. These next-generation assays improve the precision and depth of biomarker measurement, supporting studies where early detection and subtle changes in protein levels are critical.

Enhanced Sensitivity for Challenging Targets

The assays leverage enhanced detection chemistry to achieve femtogram-level sensitivity, making it possible to quantify biomarkers that are present in very low abundance in biological samples. By pushing detection limits beyond traditional immunoassays, researchers can track disease progression, monitor therapeutic responses, and better understand underlying molecular mechanisms in neurodegenerative conditions

Seamless Integration With ELLA Platform Workflows

Designed to work seamlessly on the ELLA platform, the new assays benefit from automated processing, minimal hands-on time, and high throughput. The platform’s microfluidic cartridges simplify sample handling and reduce variability, while its intuitive software supports rapid data analysis and reporting. Laboratories can run multiple assays in parallel with consistent performance and reproducibility.

Supporting Neurological Biomarker Research

These ultra-sensitive assays expand the range of detectable proteins available to investigators studying neurological disorders such as Alzheimer’s, Parkinson’s, and multiple sclerosis. By enabling reliable measurement of low-level biomarkers, the technology helps advance early diagnosis research, therapeutic development, and clinical studies that require robust quantitation of disease-associated proteins.

Improving Precision in Clinical and Translational Studies

The higher sensitivity and automated nature of the Simple Plex assays help lower technical barriers in translational research settings. Scientists can now achieve consistent biomarker profiling with less sample volume, improving efficiency and preserving precious biological material. This capability is especially valuable in studies involving cerebrospinal fluid (CSF) or other limited sample types.

Driving Discovery With Next-Gen Measurement Tools

By extending the capabilities of the ELLA platform with these ultra-sensitive assays, Bio-Techne provides researchers with powerful tools for exploring complex biological questions. The advancement supports a broad community of scientists focused on unraveling disease pathways and accelerating the development of new diagnostics and treatments.